Safety and efficacy of deferasirox in multitransfused Indian children with β-thalassaemia major

Annals of Tropical Paediatrics

Volumn 31, Issue 1, 2011, Pages 47-51

  Chandra, Jagdish ^a   Chaudhary, H ^a   Pemde, H ^a   Singh, V ^a   Dutta, A K ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ASUNRA; CREATININE; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; DESIROX; FERRITIN; IRON CHELATING AGENT; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLOOD ANALYSIS; CHILD; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIARRHEA; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; FEMALE; FERRITIN BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; HEARING DISORDER; HUMAN; HYPERPIGMENTATION; INDIA; IRON CHELATION; JAUNDICE; KIDNEY FUNCTION TEST; LABORATORY TEST; LEUKOPENIA; LIVER FUNCTION TEST; MALE; NAUSEA; NEUTROPENIA; PRESCHOOL CHILD; RASH; SCHOOL CHILD; SIDE EFFECT; SKIN PIGMENTATION; THALASSEMIA MAJOR; THROMBOCYTOPENIA; VISUAL DISORDER; VOMITING;

ADOLESCENT; BENZOIC ACIDS; BETA-THALASSEMIA; BLOOD TRANSFUSION; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INDIA; IRON CHELATING AGENTS; IRON OVERLOAD; MALE; TRIAZOLES;

EID: 79551664069     PISSN: 02724936     EISSN: 14653281     Source Type: Journal    
DOI: 10.1179/1465328110Y.0000000002     Document Type: Article

References (13)

1. Olivieri NF, Brittenham GM. Iron-chelating therapy and treatment of thalassemia. Blood 1997; 89:739-61.
2. Olivieri NF, Koren G, Hermann C, et al. Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients. Lancet 1990; 336:1275-9.
3. Iron overload. In: Cappelini MD, Cohen A, Elftheriou A, Piga A, Porter J, Taher A, eds. Guidelines for the Clinical Management of Thalassaemia. Nicosia, Cyprus: Thalassaemia International Federation, 2008; pp 33-63.
4. Agarwal MB, Gupte SS, Viswanatha C, et al. Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial. Br J Haematol 1992; 82:460-6.
5. Cohen A R, Galanello R, Piga A, De Sanctis V, Tricta F. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 2003; 102:1583-7.
6. Naithani R, Chandra J, Sharma S. Safety of oral iron chelator deferiprone in young thalassaemics. Eur J Haematol 2005; 74:217-20.
7. Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once daily oral iron chelator, in patients with beta-thalassemia. Blood 2006; 107:3455-62.
8. Piga A, Galanello R, Forni GL, et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 2006; 91:873-80.
9. Taher A, El-Bleshlawy A, Elalfy MS, et al. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia: the ESCALATOR study. Eur J Haematol 2009; 82:458-65.
10. Choudhry VP, Naithani R. Current status of iron overload and chelation with deferasirox. Indian J Pediatr 2007; 74:759-64.
11. Vichinsky E, Pakbaz Z, Onyekwere O, et al. Patient-reported outcomes of deferasirox (Exjade®, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial. Acta Haematol 2008; 119:133-41.
12. Osborne RH, De Abreu Lourenço R, Dalton A, et al. Quality of life related to oral versus sub-cutaneous iron chelation: a time trade-off study. Value Health 2007; 10:451-6.
13. Galanello R, Piga A, Forni GL, et al. Phase II clinical evaluation of deferasirox, a once daily oral chelating agent, in pediatric patients with beta-thalassemia. Haematologica 2006; 91:1343-51.